Sumbul Naz Beg, MD
Endocrinology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 4 carriers
- Offices
- 2
- Since medical school
- 29 years
- Graduated 1997
Offices
2 locations
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Beg’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
9 of 9 plans
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A78806 · Current
Licensed to practise in California · since 2002 · expires 2028-02-29 · University of the Punjab, Allama Iqbal Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$89,067
Medicare paid this office $89,067 for 81 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 81 | $88,092 | $113 |
Who their Medicare patients are
81 Original Medicare patients in 2024. Average age 72 · Women 59% · Also on Medicaid 67% · Health risk score 1.43. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 38% · Coronary heart disease 36% · Heart failure 21% · Depression 19% · Atrial fibrillation 15% · Stroke 15% · COPD 14% · Dementia 14%.
The office billed $123,895, Medicare allowed $120,318 and paid $89,067; for 794 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 81 | 794 | 72 | 1.43 | $123,895 | $89,067 |
| 2023 | 97 | 837 | 72 | 1.47 | $131,367 | $95,491 |
| 2022 | 141 | 915 | 73 | 1.40 | $145,473 | $106,158 |
| 2021 | 161 | 698 | 72 | 1.43 | $112,639 | $82,736 |
| 2020 | 178 | 2,045 | 74 | 1.74 | $129,984 | $78,951 |
| 2019 | 208 | 823 | 73 | 1.54 | $134,497 | $84,717 |
| 2018 | 201 | 797 | 75 | 1.81 | $127,129 | $74,668 |
| 2017 | 218 | 830 | 74 | 2.00 | $133,465 | $75,789 |
| 2016 | 282 | 1,159 | 73 | 2.29 | $187,827 | $111,231 |
| 2015 | 298 | 1,539 | 73 | 2.32 | $244,287 | $144,479 |
| 2014 | 342 | 2,101 | 74 | 2.46 | $330,601 | $201,904 |
| 2013 | 353 | 2,673 | 75 | 2.43 | $412,818 | $249,645 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 94 | $93,019 | $113 |
| New patient visit (45+ min) | 17 | $2,472 | $145 |
2022: 2 services
| Return visit (30+ min) | 134 | $100,919 | $115 |
| New patient visit (45+ min) | 38 | $5,238 | $138 |
2021: 2 services
| Return visit (30+ min) | 148 | $75,698 | $117 |
| New patient visit (45+ min) | 45 | $6,582 | $146 |
2020: 2 services
| Return visit (30+ min) | 167 | $72,370 | $36 |
| New patient visit (45+ min) | 43 | $5,412 | $126 |
2019: 2 services
| Return visit (30+ min) | 185 | $69,807 | $100 |
| New patient visit (45+ min) | 65 | $9,234 | $142 |
2018: 2 services
| Return visit (30+ min) | 186 | $66,873 | $92 |
| New patient visit (45+ min) | 42 | $5,497 | $131 |
2017: 3 services
| Return visit (30+ min) | 202 | $63,286 | $90 |
| New patient visit (45+ min) | 55 | $7,247 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $4,019 | $89 |
2016: 4 services
| Return visit (30+ min) | 212 | $67,775 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $27,329 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,576 | $180 |
| New patient visit (45+ min) | 49 | $7,295 | $149 |
2015: 5 services
| Return visit (30+ min) | 217 | $69,324 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $43,310 | $91 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 16 | $15,193 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $10,768 | $177 |
| New patient visit (45+ min) | 36 | $5,128 | $142 |
2014: 5 services
| Return visit (30+ min) | 248 | $81,315 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 138 | $80,083 | $92 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 28 | $20,861 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $12,555 | $179 |
| New patient visit (45+ min) | 47 | $6,956 | $148 |
2013: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 157 | $123,888 | $90 |
| Return visit (30+ min) | 248 | $73,682 | $98 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 44 | $32,602 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $11,069 | $176 |
| New patient visit (45+ min) | 45 | $6,594 | $147 |
Medicaid work
$192,511 in 2024
Medicaid paid $192,511 for 1,951 billed services this clinician did in 2024, up to 149 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 1,951 | $192,511 |
| 2024 | 1,951 | 1 | 149 | $192,511 |
| 2023 | 2,346 | 2 | 137 | $211,857 |
| 2022 | 1,964 | 2 | 126 | $174,035 |
| 2021 | 1,164 | 3 | 96 | $85,301 |
| 2020 | 1,190 | 2 | 130 | $78,683 |
| 2019 | 1,141 | 2 | 96 | $77,633 |
| 2018 | 1,064 | 2 | 92 | $73,911 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 2,332 | $209,372 |
| New patient visit (45+ min) | 14 | $2,486 |
2022
| Return visit (30+ min) | 1,927 | $169,103 |
| New patient visit (45+ min) | 37 | $4,932 |
2021
| Return visit (30+ min) | 1,064 | $76,859 |
| New patient visit (45+ min) | 84 | $8,058 |
| Alcohol and/or drug screening | 16 | $384 |
2020
| Return visit (30+ min) | 1,174 | $77,182 |
| New patient visit (45+ min) | 16 | $1,501 |
2019
| Return visit (30+ min) | 1,038 | $64,382 |
| New patient visit (45+ min) | 103 | $13,252 |
2018
| Return visit (30+ min) | 958 | $60,538 |
| New patient visit (45+ min) | 106 | $13,373 |
Drugs they prescribed that Part D paid
$221,651
Pharmacies billed $221,651 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 816) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
277 generic and 418 brand-name prescriptions · $221,651 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 51 | $51,135 | $1,003 |
| Trulicity | 19 | $22,185 | $1,168 |
| Jardiance | 13 | $20,075 | $1,544 |
| Cinacalcet | 15 | $16,405 | $1,094 |
| Basaglar Kwikpen U-100 | 41 | $13,090 | $319 |
See all 21 drugs
| Ozempic | 51 | $51,135 | $1,003 |
| Trulicity | 19 | $22,185 | $1,168 |
| Jardiance | 13 | $20,075 | $1,544 |
| Cinacalcet | 15 | $16,405 | $1,094 |
| Basaglar Kwikpen U-100 | 41 | $13,090 | $319 |
| Tresiba Flextouch U-100 | 20 | $10,202 | $510 |
| Fiasp Flextouch | 19 | $9,468 | $498 |
| Admelog Solostar | 35 | $8,721 | $249 |
| Nano 2nd Gen Pen Needle | 59 | $7,376 | $125 |
| Insulin Glargine-Yfgn | 66 | $6,539 | $99 |
| Nateglinide | 54 | $5,212 | $97 |
| Insulin Lispro Kwikpen U-100 | 24 | $4,247 | $177 |
| Lantus Solostar | 29 | $3,761 | $130 |
| Humalog Kwikpen U-100 | 20 | $3,103 | $155 |
| Pen Needles | 12 | $2,505 | $209 |
| Ultra-Fine Mini Pen Needle | 20 | $2,186 | $109 |
| Metformin | 64 | $762 | $12 |
| Levothyroxine | 37 | $461 | $12 |
| Glipizide | 36 | $221 | $6 |
| Alendronate | 17 | $220 | $13 |
| Methimazole | 26 | $140 | $5 |
Year by year
| 2024 | 816 | 111 | 0% (0) | 51% | $221,651 |
| 2023 | 884 | 139 | 0% (0) | 51% | $287,708 |
| 2022 | 989 | 178 | 0% (0) | 51% | $328,048 |
| 2021 | 1,180 | 201 | 0% (0) | 51% | $376,518 |
| 2020 | 1,221 | 184 | 0% (0) | 48% | $404,639 |
| 2019 | 1,267 | 206 | None | 48% | $405,882 |
| 2018 | 1,201 | 210 | 0% (0) | 49% | $373,448 |
| 2017 | 1,217 | 205 | 0% (0) | 50% | $372,728 |
| 2016 | 1,147 | 197 | 0% (0) | 50% | $336,778 |
| 2015 | 1,162 | 182 | 0% (0) | 49% | $309,820 |
| 2014 | 1,146 | 183 | 0% (0) | 47% | $289,722 |
| 2013 | 1,537 | 236 | 0% (0) | 47% | $309,666 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Ozempic | 31 | $31,379 | $1,012 |
| Lantus Solostar | 44 | $29,841 | $678 |
| Cinacalcet | 22 | $26,857 | $1,221 |
| Novolog Flexpen | 29 | $17,710 | $611 |
| Trulicity | 13 | $17,456 | $1,343 |
| Jardiance | 14 | $16,919 | $1,208 |
| Nateglinide | 106 | $13,640 | $129 |
| Tresiba Flextouch U-100 | 22 | $11,522 | $524 |
| Insulin Glargine-Yfgn | 83 | $10,803 | $130 |
| Fiasp Flextouch | 14 | $8,434 | $602 |
| Basaglar Kwikpen U-100 | 23 | $8,433 | $367 |
| Insulin Lispro Kwikpen U-100 | 38 | $6,455 | $170 |
| Insulin Aspart Flexpen | 18 | $5,468 | $304 |
| Humalog Kwikpen U-100 | 11 | $5,297 | $482 |
| Nano 2nd Gen Pen Needle | 35 | $4,321 | $123 |
| Admelog Solostar | 19 | $4,293 | $226 |
| Metformin | 83 | $2,554 | $31 |
| Ultra-Fine Mini Pen Needle | 26 | $2,362 | $91 |
| Pen Needles | 11 | $2,278 | $207 |
| Levothyroxine | 44 | $796 | $18 |
| Calcitriol | 12 | $530 | $44 |
| Glimepiride | 18 | $448 | $25 |
| Glipizide | 20 | $286 | $14 |
| Methimazole | 11 | $116 | $11 |
2022: 21 drugs
| Lantus Solostar | 172 | $87,413 | $508 |
| Cinacalcet | 26 | $35,718 | $1,374 |
| Prolia | 18 | $26,107 | $1,450 |
| Novolog Flexpen | 38 | $23,764 | $625 |
| Nateglinide | 113 | $16,168 | $143 |
| Insulin Aspart Flexpen | 33 | $10,768 | $326 |
| Humalog Kwikpen U-100 | 18 | $9,564 | $531 |
| Lantus | 28 | $8,805 | $314 |
| Tresiba Flextouch U-100 | 12 | $7,486 | $624 |
| Nano 2nd Gen Pen Needle | 40 | $4,301 | $108 |
| Insulin Lispro Kwikpen U-100 | 25 | $4,287 | $171 |
| Ultra-Fine Mini Pen Needle | 29 | $3,375 | $116 |
| Admelog Solostar | 13 | $3,245 | $250 |
| Ultra-Fine Short Pen Needle | 16 | $2,140 | $134 |
| Pen Needles | 12 | $2,121 | $177 |
| Metformin | 86 | $2,035 | $24 |
| Levothyroxine | 91 | $1,813 | $20 |
| Insulin Lispro | 12 | $998 | $83 |
| Calcitriol | 11 | $425 | $39 |
| Glipizide | 22 | $294 | $13 |
| Methimazole | 13 | $137 | $11 |
2021: 20 drugs
| Lantus Solostar | 210 | $105,034 | $500 |
| Humalog Kwikpen U-100 | 49 | $32,567 | $665 |
| Cinacalcet | 43 | $31,488 | $732 |
| Prolia | 14 | $19,114 | $1,365 |
| Nateglinide | 126 | $15,647 | $124 |
| Insulin Lispro Kwikpen U-100 | 44 | $14,656 | $333 |
| Novolog Flexpen | 23 | $13,050 | $567 |
| Tresiba Flextouch U-100 | 22 | $12,334 | $561 |
| Lantus | 25 | $7,581 | $303 |
| Basaglar Kwikpen U-100 | 20 | $5,789 | $289 |
| Toujeo Solostar | 12 | $4,992 | $416 |
| Ultra-Fine Mini Pen Needle | 33 | $4,129 | $125 |
| Nano 2nd Gen Pen Needle | 40 | $3,287 | $82 |
| Pen Needles | 19 | $3,009 | $158 |
| Ultra-Fine Short Pen Needle | 24 | $2,773 | $116 |
| Levothyroxine | 103 | $2,346 | $23 |
| Metformin | 100 | $2,305 | $23 |
| Synthroid | 14 | $1,448 | $103 |
| Glimepiride | 29 | $740 | $26 |
| Glipizide | 27 | $469 | $17 |
2020: 24 drugs
| Lantus Solostar | 193 | $105,602 | $547 |
| Novolog Flexpen | 30 | $34,991 | $1,166 |
| Cinacalcet | 49 | $32,289 | $659 |
| Humalog Kwikpen U-100 | 42 | $30,220 | $720 |
| Nateglinide | 131 | $17,524 | $134 |
| Tresiba Flextouch U-100 | 27 | $15,918 | $590 |
| Levemir Flextouch | 12 | $13,355 | $1,113 |
| Basaglar Kwikpen U-100 | 29 | $13,183 | $455 |
| Lantus | 29 | $9,625 | $332 |
| Farxiga | 13 | $8,098 | $623 |
| Insulin Lispro Kwikpen U-100 | 19 | $7,707 | $406 |
| Toujeo Solostar | 21 | $6,962 | $332 |
| Ultra-Fine Mini Pen Needle | 34 | $4,406 | $130 |
| Pen Needles | 24 | $3,561 | $148 |
| Ultra-Fine Nano Pen Needle | 41 | $3,048 | $74 |
| Levothyroxine | 117 | $2,869 | $25 |
| Metformin | 106 | $2,077 | $20 |
| Ultra-Fine Short Pen Needle | 21 | $2,069 | $99 |
| Synthroid | 15 | $1,372 | $91 |
| Nano 2nd Gen Pen Needle | 14 | $909 | $65 |
| Metformin Hcl Er | 15 | $377 | $25 |
| Glipizide | 19 | $357 | $19 |
| Glimepiride | 21 | $273 | $13 |
| Methimazole | 16 | $160 | $10 |
2019: 25 drugs
| Lantus Solostar | 161 | $88,302 | $548 |
| Humalog Kwikpen U-100 | 83 | $77,147 | $929 |
| Lantus | 46 | $26,748 | $581 |
| Nateglinide | 119 | $19,370 | $163 |
| Levemir Flextouch | 20 | $18,752 | $938 |
| Cinacalcet | 28 | $18,492 | $660 |
| Prolia | 15 | $18,390 | $1,226 |
| Novolog Flexpen | 20 | $15,154 | $758 |
| Sensipar | 18 | $14,795 | $822 |
| Basaglar Kwikpen U-100 | 24 | $9,321 | $388 |
| Novolog | 11 | $8,400 | $764 |
| Tresiba Flextouch U-100 | 12 | $7,610 | $634 |
| Farxiga | 12 | $6,039 | $503 |
| Pen Needles | 35 | $5,280 | $151 |
| Levothyroxine | 148 | $3,620 | $24 |
| Ultra-Fine Nano Pen Needle | 40 | $3,348 | $84 |
| Ultra-Fine Short Pen Needle | 31 | $2,972 | $96 |
| Ultra-Fine Mini Pen Needle | 29 | $2,563 | $88 |
| Metformin | 97 | $1,606 | $17 |
| Synthroid | 16 | $1,428 | $89 |
| Glipizide | 37 | $482 | $13 |
| Insulin | 11 | $440 | $40 |
| Metformin Hcl Er | 18 | $369 | $21 |
| Methimazole | 21 | $288 | $14 |
| Glimepiride | 32 | $263 | $8 |
2018: 26 drugs
| Lantus Solostar | 144 | $87,045 | $604 |
| Humalog Kwikpen U-100 | 60 | $63,934 | $1,066 |
| Nateglinide | 150 | $22,852 | $152 |
| Lantus | 46 | $21,107 | $459 |
| Toujeo Solostar | 21 | $19,624 | $934 |
| Sensipar | 18 | $18,212 | $1,012 |
| Novolog Flexpen | 27 | $16,393 | $607 |
| Prolia | 13 | $15,373 | $1,183 |
| Levemir Flextouch | 21 | $12,677 | $604 |
| Basaglar Kwikpen U-100 | 19 | $9,401 | $495 |
| Novolog | 19 | $9,168 | $483 |
| Levemir | 12 | $7,379 | $615 |
| Humalog | 13 | $5,854 | $450 |
| Levothyroxine | 155 | $4,002 | $26 |
| Ultra-Fine Short Pen Needle | 38 | $3,030 | $80 |
| Pen Needles | 29 | $2,850 | $98 |
| Ultra-Fine Mini Pen Needle | 26 | $2,555 | $98 |
| Ultra-Fine Nano Pen Needle | 30 | $2,311 | $77 |
| Metformin | 80 | $1,636 | $20 |
| Synthroid | 16 | $1,121 | $70 |
| Liothyronine | 12 | $997 | $83 |
| Insulin | 15 | $439 | $29 |
| Methimazole | 22 | $294 | $13 |
| Glipizide | 36 | $276 | $8 |
| Hydrocortisone | 13 | $241 | $19 |
| Glimepiride | 15 | $159 | $11 |
2017: 26 drugs
| Lantus Solostar | 206 | $106,756 | $518 |
| Humalog Kwikpen U-100 | 71 | $69,515 | $979 |
| Lantus | 64 | $31,518 | $492 |
| Sensipar | 14 | $26,721 | $1,909 |
| Nateglinide | 144 | $20,074 | $139 |
| Toujeo Solostar | 18 | $19,451 | $1,081 |
| Prolia | 13 | $14,318 | $1,101 |
| Novolog Flexpen | 21 | $13,496 | $643 |
| Humalog | 26 | $11,701 | $450 |
| Novolog | 15 | $8,083 | $539 |
| Levemir Flextouch | 13 | $6,981 | $537 |
| Levothyroxine | 142 | $4,068 | $29 |
| Pen Needles | 25 | $2,857 | $114 |
| Ultra-Fine Mini Pen Needle | 26 | $2,446 | $94 |
| Ultra-Fine Short Pen Needle | 33 | $2,347 | $71 |
| Ultra-Fine Nano Pen Needle | 25 | $1,745 | $70 |
| Metformin | 62 | $1,197 | $19 |
| Synthroid | 22 | $1,140 | $52 |
| Insulin | 12 | $861 | $72 |
| Insulin | 12 | $403 | $34 |
| Atorvastatin | 22 | $335 | $15 |
| Glipizide | 23 | $330 | $14 |
| Methimazole | 11 | $329 | $30 |
| Hydrocortisone | 25 | $329 | $13 |
| Glimepiride | 13 | $125 | $10 |
| Metformin Hcl Er | 11 | $121 | $11 |
2016: 22 drugs
| Lantus Solostar | 163 | $104,682 | $642 |
| Humalog Kwikpen U-100 | 71 | $51,190 | $721 |
| Sensipar | 30 | $44,421 | $1,481 |
| Lantus | 78 | $35,643 | $457 |
| Nateglinide | 152 | $26,881 | $177 |
| Humalog | 24 | $11,460 | $478 |
| Prolia | 11 | $10,995 | $1,000 |
| Levemir Flextouch | 11 | $6,544 | $595 |
| Levemir | 11 | $5,533 | $503 |
| Bd Ultra-Fine Pen Needle | 67 | $5,481 | $82 |
| Levothyroxine | 139 | $3,694 | $27 |
| Liothyronine | 20 | $1,354 | $68 |
| Synthroid | 26 | $1,144 | $44 |
| Hydrocortisone | 20 | $926 | $46 |
| Metformin | 63 | $905 | $14 |
| Easy Touch Pen Needle | 18 | $760 | $42 |
| Calcitriol | 19 | $760 | $40 |
| Atorvastatin | 26 | $705 | $27 |
| Insulin | 18 | $565 | $31 |
| Methimazole | 12 | $288 | $24 |
| Insulin | 11 | $275 | $25 |
| Glipizide | 15 | $165 | $11 |
2015: 24 drugs
| Lantus Solostar | 126 | $68,827 | $546 |
| Lantus | 103 | $54,757 | $532 |
| Sensipar | 21 | $43,537 | $2,073 |
| Nateglinide | 159 | $27,859 | $175 |
| Humalog Kwikpen U-100 | 37 | $20,766 | $561 |
| Humalog | 34 | $17,173 | $505 |
| Novolog Flexpen | 13 | $5,293 | $407 |
| Janumet | 12 | $4,144 | $345 |
| Bd Ultra-Fine Pen Needle | 56 | $3,926 | $70 |
| Levothyroxine | 148 | $3,393 | $23 |
| Liothyronine | 35 | $1,765 | $50 |
| Hydrocortisone | 14 | $1,427 | $102 |
| Synthroid | 31 | $1,196 | $39 |
| Acarbose | 19 | $905 | $48 |
| Metformin | 61 | $730 | $12 |
| Insulin | 20 | $698 | $35 |
| Insulin | 15 | $670 | $45 |
| Insulin | 15 | $648 | $43 |
| Potassium Chloride | 12 | $579 | $48 |
| Methimazole | 39 | $547 | $14 |
| Atorvastatin | 15 | $431 | $29 |
| Easy Touch Pen Needle | 15 | $389 | $26 |
| Glimepiride | 18 | $313 | $17 |
| Simvastatin | 13 | $157 | $12 |
2014: 23 drugs
| Lantus | 117 | $67,443 | $576 |
| Lantus Solostar | 110 | $58,269 | $530 |
| Saizen | 12 | $34,560 | $2,880 |
| Nateglinide | 172 | $33,491 | $195 |
| Sensipar | 18 | $17,603 | $978 |
| Humalog | 39 | $16,979 | $435 |
| Prolia | 16 | $13,917 | $870 |
| Januvia | 22 | $9,286 | $422 |
| Novolog | 18 | $3,822 | $212 |
| Levothyroxine | 145 | $2,999 | $21 |
| Bd Ultra-Fine Pen Needle | 48 | $2,321 | $48 |
| Metformin | 85 | $1,570 | $18 |
| Hydrocortisone | 20 | $1,525 | $76 |
| Acarbose | 13 | $1,388 | $107 |
| Synthroid | 28 | $1,245 | $44 |
| Liothyronine | 14 | $1,137 | $81 |
| Insulin | 21 | $734 | $35 |
| Atorvastatin | 15 | $544 | $36 |
| Insulin | 16 | $485 | $30 |
| Insulin | 16 | $440 | $27 |
| Lisinopril | 13 | $161 | $12 |
| Glimepiride | 13 | $154 | $12 |
| Glipizide | 17 | $147 | $9 |
2013: 25 drugs
| Lantus | 150 | $55,360 | $369 |
| Januvia | 124 | $54,337 | $438 |
| Lantus Solostar | 124 | $53,293 | $430 |
| Nateglinide | 179 | $37,540 | $210 |
| Humalog | 51 | $20,588 | $404 |
| Sensipar | 17 | $12,189 | $717 |
| Prolia | 14 | $11,883 | $849 |
| Novolog | 14 | $4,797 | $343 |
| Janumet | 12 | $3,296 | $275 |
| Metformin | 123 | $3,129 | $25 |
| Bd Ultra-Fine Pen Needle | 50 | $2,523 | $50 |
| Acarbose | 18 | $2,444 | $136 |
| Levothyroxine | 156 | $2,235 | $14 |
| Liothyronine | 19 | $1,400 | $74 |
| Hydrocortisone | 22 | $1,034 | $47 |
| Synthroid | 28 | $1,011 | $36 |
| Insulin | 30 | $654 | $22 |
| Insulin | 25 | $642 | $26 |
| Insulin | 14 | $514 | $37 |
| Vitamin D2 | 51 | $508 | $10 |
| Lisinopril | 29 | $315 | $11 |
| Glimepiride | 21 | $247 | $12 |
| Pravastatin | 11 | $225 | $20 |
| Polyethylene Glycol 3350 | 15 | $201 | $13 |
| Glipizide | 13 | $139 | $11 |
Money from drug and device companies
$98 in 2025
| 2025 | 1 | 1 | None | $98 |
| 2024 | 1 | 3 | None | $43 |
| 2023 | 1 | 1 | None | $18 |
| 2022 | 4 | 5 | None | $88 |
| 2021 | 2 | 3 | None | $58 |
| 2019 | 5 | 7 | None | $115 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tavneos | $98 | 1 payment
|
See the published payment
| Amgen | Meals · 2025-07-14 | Tavneos | $98 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $43
| Dexcom | Dexcom G6 Transmitter | $43 | 3 payments
|
2023: $18
| MannKind | Afrezza | $18 | 1 payment
|
2022: $88
| Mannkind | Afrezza | $32 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $22 | 1 payment
|
| Sanofi-Aventis U.S. | Toujeo | $21 | 1 payment
|
| Novo Nordisk | Rybelsus | $13 | 1 payment
|
2021: $58
| Becton Dickinson and | Bd Nano | $39 | 2 payments
|
| MannKind | Afrezza | $19 | 1 payment
|
2019: $115
| Mannkind | Afrezza | $30 | 2 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $29 | 2 payments
|
| Lilly USA | Humulin | $25 | 1 payment
|
| Insulet | Omnipod | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $12 | 1 payment
|
Professional record
- NPI
- 1437127560
- Licence
- CA A78806California A78806: Current · expires 2028-02-29
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 1534 Plaza Ln # 306, Burlingame, CA, 94010
- NPI first listed
- 2006-03-14
- NPI last updated
- 2023-12-01
- NPI record certified
- 2023-12-01
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3755 Beacon Ave, Fremont, CA, 94538